Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
|Videos|May 25, 2015
Dr. Kandil on Minimally Invasive Surgical Techniques
Author(s)Emad Kandil, MD
Emad Kandil, MD, Chief of Endocrine Surgery at the Tulane University School of Medicine, discusses advances in surgical procedures.
Advertisement
Emad Kandil, MD, Chief of Endocrine Surgery at the Tulane University School of Medicine, discusses advances in surgical procedures.
A positive oncological outcome is the main goal when performing a surgical procedure on a patient with a cancer diagnosis, says Kandil. Surgeons aim to reduce chance for reoccurrence as much as possible and improve survival.
New technologies now offer minimally invasive techniques that can reduce scar tissue and recovering times for patients, while still providing positive oncological outcome.
Advertisement
Related to this article
Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss optimizing first-line treatment selection and second-line sequencing in EGFR-mutated NSCLC.
MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Three new articles from The Lancet Hematology published today examine how clinicians and researchers can better identify, track and measure the effects of blood cancer treatments on patients during treatment and over the long term.
During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
R. Lor Randall, MD, FACS, discusses novel precision surgery techniques that are making progress in sarcoma care.
Advertisement
Advertisement
Trending on OncLive
1
European Commission Approves T-DXd Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
2
Dr Huffman on the Mechanism of Action of INCB161734 in KRAS G12D–Mutated Metastatic Pancreatic Cancer
3
TP53 Status and Treatment Toxicity Burden Guide Sequencing in EGFR-Mutated NSCLC
4
FDA Grants Fast Track Designation to MT027 for Recurrent Glioblastoma
5